Livagen
Also known as: Lys-Glu, Khavinson liver peptide, Hepatic bioregulator, Livagen dipeptide
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
Short (minutes); gene-regulatory effects are sustained
Route
SubQ, Oral
Category
Anti-Aging & Longevity
Studies
7 references
Key Benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
Mechanism of Action
Livagen's dipeptide Lys-Glu interacts with chromatin in hepatocytes and thymic cells, acting as a gene expression modulator. In liver cells, it normalizes protein synthesis, reduces hepatocyte apoptosis, and promotes regeneration. In thymic tissue, it supports T-lymphocyte development and immune maturation. The dual hepatic-immune action makes it useful in protocols addressing both liver health and immune aging.
Dosing Protocols
Standard Khavinson Protocol
- Dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
- Timing
- Subcutaneous injection or oral (enteric-coated)
- Cycle
- 10–30 day course, repeated 2–4x per year
Often combined with Ovagen for hepatic protocols, and Epithalon for anti-aging. Research use only.
Calculate your draw volume
Enter your vial size and BAC water to get exact injection volumes
Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
Contraindications
Not FDA approved. Not a substitute for antiviral therapy in hepatitis or standard hepatology care. Medical supervision recommended for active liver disease.
Storage
Store at 2–8°C. Protect from moisture and light.
Clinical Research
- 1.EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN
Lezhava T, Jokhadze T, Monaselidze J, Buadze T, Gaiozishvili M, Sigua T et al. · Georgian medical news · 2023PubMed Verified
- 2.Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan
Khavinson VK, Kormilets DY, Mar'yanovich AT · Bulletin of experimental biology and medicine · 2017PubMed Verified
- 3.Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals
Lezhava T, Jokhadze T · Annals of the New York Academy of Sciences · 2007PubMed Verified
- 4.Anti-aging peptide bioregulators induce reactivation of chromatin
Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T · Georgian medical news · 2006PubMed Verified
- 5.Effects of short peptides on lymphocyte chromatin in senile subjects
Khavinson VKh, Lezhava TA, Malinin VV · Bulletin of experimental biology and medicine · 2004PubMed Verified
- 6.Effects of Livagen peptide on chromatin activation in lymphocytes from old people
Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK et al. · Bulletin of experimental biology and medicine · 2002PubMed Verified
- 7.Tissue-specific effects of peptides
Khavinson VK · Bulletin of experimental biology and medicine · 2001PubMed Verified
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.
Was this page helpful?
Launching soon
Build and track your protocol in Staqk
Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.